Quale sarebbe il prezzo per Clover Biopharmaceuticals, Ltd. (2197)

Il prezzo per Clover Biopharmaceuticals, Ltd. (2197) è $0.25841098

Qual è la capitalizzazione di mercato per Clover Biopharmaceuticals, Ltd. (2197)

La capitalizzazione di mercato per Clover Biopharmaceuticals, Ltd. (2197) è $335.38M

Clover Biopharmaceuticals, Ltd. (2197) Prezzo e Capitalizzazione di Mercato

Clover Biopharmaceuticals, Ltd. is a biotechnology enterprise focused on discovering, developing, and commercializing innovative vaccines and biological therapies. Their efforts target infectious diseases, various cancers, and autoimmune conditions. The company's pipeline features several key candidates: SCB-2019 (CpG 1018/Alum): A COVID-19 vaccine candidate currently advancing through Phase II/III clinical trials. SCB-313: A trimeric fusion protein aimed at treating severe intracavitary malignancies, including malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis, addressing a significant global medical need. SCB-808: Undergoing pivotal Phase III clinical trials for the management of rheumatic disorders. SCB-420: An aflibercept biosimilar in preclinical development for ophthalmologic conditions like wet age-related macular degeneration. SCB-219: A novel TPOR agonist in preclinical stages for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. Clover also holds a collaboration and supply agreement with Dynavax, which provides its CpG 1018 adjuvant for use in preclinical studies. The company was established in 2007 and is based in Shanghai, China.

Il prezzo per 2197	Attivo B	Capitalizzazione del mercato a B	Risultati
$4,065.52 $335.38M	NVDA	$5.276T	+1,573,176.68%
$3,679.32 $335.38M	AAPL	$4.775T	+1,423,724.09%
$3,113.90 $335.38M	GOOG	$4.041T	+1,204,916.97%
$2,881.70 $335.38M	MSFT	$3.740T	+1,115,060.01%
$2,114.89 $335.38M	AMZN	$2.745T	+818,321.12%

Il prezzo per 2197

Attivo B

Capitalizzazione del mercato a B

Risultati

$4,065.52 $335.38M